| 词条 | Vascular-targeting agent |
| 释义 |
A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.[1] VTAs can be small-molecule or ligand-based. Small-molecule VTAs include:
Clinical trialsPhase II : ZD6126, CA4P, plinabulin (NPI-2358)[2][3][4] Phase III : DMXAA (ASA404). References1. ^{{cite journal |url=http://clincancerres.aacrjournals.org/cgi/reprint/10/2/415.pdf |title=Vascular Targeting Agents as Cancer Therapeutics |year=2004 }} {{antineoplastic-drug-stub}}2. ^{{cite web | title = NPI-2358 | url = http://clinicaltrials.gov/ct2/results?term=NPI-2358&Search=Search | publisher = clinicaltrials.gov}} 3. ^{{Cite journal | title = Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas | author = Monica M. Mita| doi= 10.1158/1078-0432.CCR-10-1096 |journal = Clin Cancer Res | year = 2010 | volume = 16 | issue = 23 | pages = 5892–5899 | pmid=21138873|display-authors=etal}} 4. ^{{Cite journal | title = Clinical Trials Update | year = 2009 | author = Staff | journal = Genetic Engineering & Biotechnology News | pages = 58 | volume = 29 | issue = 8}} 2 : Cancer treatments|Drugs acting on the cardiovascular system |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。